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Cheng-Ta Hsieh and Da-Tong Ju
Abstract
Glioblastoma multiforme (GBM) is the most aggressive intracranial tumor that
primarily affects adults. Since the introduction of temozolomide in 2005, maximal
resection surgery with concurrent chemoradiation has become the standard treat-
ment method for patients with newly diagnosed GBM. Although newly discovered
chemoagents have been demonstrated to improve the median survival time, GBM
still recurs in most patients. Recurrent GBM is still a therapeutic challenge for
clinical physicians. Surgical intervention and other conventional chemoagents have
been applied to manage recurrent GBM. Stereotactic radiosurgery (SRS) provides a
highly precise radiation dose to the tumor lesion and reduces the dose to the
adjacent normal brain tissue. After standard treatment for newly diagnosed GBM is
completed, conventional re-irradiation therapy is not suitable for patients with
recurrent GBMs. Therefore, SRS may become an alternative option in the treatment
of recurrent GBMs. In this review, we discuss the relevant literature regarding SRS
for recurrent GBMs and provide treatment advice for clinical physicians.
Keywords: stereotactic radiosurgery, recurrent glioblastoma multiforme,
re-irradiation, survival time, prognosis
1. Introduction
Glioblastoma multiforme (GBM) is the most common primary brain neoplasm
in adults [1, 2]. There are 1.6 times more males than females who develop a GBM
[1]. According to the latest statistical report of the Central Brain Tumor Registry of
the USA, the annual incidence of GBM has been estimated at approximately 3.22
cases per 100,000 people, and the median age is 65 years [3]. The current standard
treatment of patients with a newly diagnosed GBM was established in 2005, and it
consists of maximal surgical resection of the tumor followed by chemotherapy and
conventional radiotherapy [4, 5]. Despite this therapy, the median overall survival
time is approximately 15–17 months [2].
GBM is a refractory malignant and infiltrating tumor that may recur any time
after initial multimodal treatments are completed [6]. Managing recurrent GBM has
always been challenging, and a balance has to be achieved between significant
treatment toxicity and associated morbidities and mortalities [6, 7]. Reoperation
with maximal resection at recurrence remains as an independent predictor to
improve overall survival [8, 9]. However, repeat gross-total resection may not be
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easily achieved when recurrent GBM involves important eloquent brain structures,
such as the brainstem or motor area. Extensive bevacizumab and temozolomide are
the two main FDA-approved chemoagents used to treat patients with recurrent
GBMs, but the prognosis remains poor [10].
Re-irradiation is an alternative option for managing recurrent GBMs [11]. The
majority of recurrent tumors occur at the initial or adjacent regional sites [12].
Because a total dose of 60 Gy in 30 fractions has been prescribed for initial radiation
therapy, re-irradiation with further dose escalation appears to produce more signif-
icant toxicity [10, 11]. Stereotactic radiosurgery (SRS) is a noninvasive treatment
that provides a highly precise, targeted additional radiation boost to the tumor
lesion, and it maintains an acceptable rate of adverse radiation effects while reduc-
ing the dose to adjacent normal brain tissues [13]. In this review, we searched the
relevant literature and investigated the role of SRS in the management of recurrent
GBMs. Our results may provide treatment information for clinical treatment.
2. Search methodology
In this study, different combinations of the keywords “recurrent glioblastoma
multiple,” “high-grade glioma,” “stereotactic radiosurgery,” and “re-irradiation”were
used to search the published literature in the PubMed database until October 31, 2019.
The inclusion criteria of the study were (1) patients with recurrent GBMs, (2) treat-
ment with stereotactic radiosurgery (SRS) or a fractionated radiosurgery (less than 5
fractions), and (3) outcomes with overall survival time. Tumor progression was also
accepted as a recurrent disease. Potentially relevant studies were identified from the
reference lists of the studies obtained from the database search. Articles excluded from
the review were those written in languages other than English and those that lacked
survival response data. Finally, a total of 49 studies were included in this review.
3. The summary of patients with recurrent GBMs treated with SRS
A total of 49 studies published from 1994 to 2019 were enrolled in this review, as
summarized in Table 1 [13–61]. There were 6 prospective studies and 43 retro-
spective studies. About 2066 patients with recurrent glioblastomas treated with
SRS, including linear accelerator (LINAC) radiosurgery, Gamma Knife radiosur-
gery, and Cyberknife radiosurgery, are reported. In all studies, the median age of
the patients who received SRS treatment for recurrent GBM ranged from 34 to
62 years. The majority of patients were males. The median prescribed dose of SRS
ranged from 6 to 30 Gy. The median targeted volume for treatment ranged from
1.35 to 21.3 cc. The overall survival time from treatment for SRS ranged from 3.9 to
17.9 months, where the progression-free survival time from the treatment of SRS
ranged from 2.1 to 14.9 months. In the prognostic analysis of survival time in
patients with recurrent GBMs treated with SRS, a small tumor volume, younger age,
higher Karnofsky performance scale (KPS) score, lower recursive partitioning
analysis (RPA) class, adjuvant bevacizumab, methylated O6-methylguanine-DNA-
methyltransferase (MGMT) promoter, and longer interval between the original
surgery and SRS were significantly associated with patients’ survival outcomes.
3.1 The effect of LINAC radiosurgery in patients with recurrent GBMs
From 1994 to 2018, a total of 501 patients with recurrent GBMs treated with
LINAC SRS were enrolled in 22 studies, including 3 prospective trials and 17
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retrospective studies [14–16, 19, 21, 23–26, 28, 32, 33, 35, 39, 40, 43, 49, 51, 54, 56,
60, 61]. The median age ranged from 34 to 54 years. The median prescribed dose
ranged from 13 to 30 Gy. The median targeted tumor volume was 4.5 to 41.3 cc. The
median overall survival time from the treatment of SRS ranged from 3.9 to
14.4 months, whereas the median progression-free survival time was 2.1 to
11 months.
The first study about LINAC radiosurgery for recurrent GBMs was described by
Chamerian et al. [14]. The median prescribed dose was 13.4 Gy, and the median
treated tumor volume was 17 cc. The median overall survival time was only
8 months, whereas the median progression-free survival time was 4 months. After
that, only one retrospective study of more than 100 patients with recurrent high-
grade gliomas treated with LINAC SRS has been reported [16]. Shrieve et al. showed
that the median survival time of 72 recurrent GBM patients was 10.2 months [16].
Younger age (less than 46 years) and small tumor volume (less than 10.1 cc) were
the significant prognostic factors associated with survival time. There were two
studies that enrolled patients with only recurrent GBMs [21, 33]. In 2005, Combs
et al. reported 32 patients, including 19 males and 13 females with recurrent GBMs
treated with LINAC SRS [21]. The median age was 56 years, ranging from 33 to
76 years. The median prescribed radiation dose was 15 Gy, ranging from 10 to
20 Gy. The median targeted tumor volume was 10 cc with a range of 1.2 to 59.2 cc.
The median overall survival time and progression-free survival time were 10 and
5 months, respectively. However, no prognostic factor was significant enough to
influence the survival time. In a retrospective study of 19 patients with recurrent
GBMs, Sirin et al. also showed that the median overall survival time and
progression-free survival time were only 9.3 and 5.7 months, respectively [33]. In
the bevacizumab era, three studies reported the combination of LINAC SRS, and
bevacizumab improved the overall survival time ranging from 11.2 to 14.4 months
[35, 39, 40]. In a retrospective study of 48 patients with recurrent GBMs, Cuneo
et al. reported that the median progression-free survival time in recurrent patients
who received adjuvant bevacizumab and LINAC SRS was 5.2 months vs. 2.1 months
for patients who received LINAC SRS alone. The median overall survival times for
patients who received a combination of adjuvant bevacizumab/LINAC SRS and
LINAC SRS alone were 11.2 and 3.9 months, respectively. The authors concluded
that the combination of salvage radiosurgery and bevacizumab to treat recurrent
malignant gliomas seemed to be associated with improved outcomes. Younger age
and higher KPS were still significant prognostic factors associated with overall
survival time in patients with recurrent GBMs.
3.2 The effect of gamma knife radiosurgery in patients with recurrent GBMs
From 1996 to 2019, a total of 1247 patients with recurrent GBMs in 23 published
studies were treated with Gamma Knife SRS [13, 17, 18, 20, 22, 24, 27, 29, 31, 36–
38, 41, 45, 47, 50, 52, 53, 55, 57–59, 61]. The median age ranged from 43 to 61 years.
The median prescribed marginal dose varied from 6 to 20 Gy. The median targeted
tumor volume ranged from 1.35 to 21.4 cc. The median overall survival time ranged
from 7 to 30 months, whereas the median progression-free survival time ranged
from 3.8 to 14.9 months.
In a retrospective study of 189 patients with recurrent high-grade gliomas
treated with Gamma Knife SRS, Larson et al. first reported that the median overall
survival time in 66 patients with recurrent GBMs was 10 months [17]. Younger age,
smaller tumor volume, higher KPS, and unifocal tumors were significant prognostic
factors associated with patients’ overall survival times. Several studies reported the
impact of a combination of Gamma Knife SRS and adjuvant chemoagents on overall
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survival times [17, 37, 47, 55, 59]. In 2002, Larson et al. reported a prospective phase
II study on patients who received a combination of Gamma Knife SRS, and
marimastat had a median overall survival of 8.7 months, whereas the median sur-
vival time in patients who received only Gamma Knife SRS alone was 10.1 months.
Marimastat did not offer an advantage for patients with recurrent GBMs. However,
in a retrospective study of 57 patients with recurrent GBMs, Kim et al. showed that
the combination of adjuvant temozolomide and Gamma Knife SRS significantly
improved the medium overall survival time from 9.2 to 15.5 months [47]. In the
bevacizumab era, two studies reported that the median survival time was approxi-
mately 13 months after the combined treatment of Gamma Knife SRS and adjuvant
bevacizumab [55, 59].
3.3 The effect of Cyberknife radiosurgery in patients with recurrent GBMs
From 2009 to 2017, a total of 318 patients with recurrent GBMs in eight published
studies were treated with Cyberknife SRS [30, 34, 42, 44, 46, 48, 51, 54]. The median
age ranged from 37 to 59.9 years. The median prescribed marginal dose ranged from
15 to 30 Gy. The median targeted tumor volume ranged from 2 to 24 cc. The median
overall survival time after Cyberknife SRS ranged from 5.3 to 12 months, whereas the
median progression-free survival time ranged from 4 to 7.9 months.
The first report on Cyberknife SRS for patients with recurrent GBMs was
published by Villavicencio et al. [30]. The median overall survival time in a total of
26 patients with recurrent GBMs was 7 months. No prognostic factor associated
with the overall survival time was identified. In 2015, Pinzi et al. reported a retro-
spective study of more than 100 patients who had recurrent high-grade glioma
treated with Cyberknife SRS [48]. Among 88 patients with recurrent GBMs, the
median survival time was 10 months after treatment with Cyberknife SRS. Adju-
vant second-line chemotherapy and/or surgery were the significant prognostic fac-
tors associated with overall survival times. The effect of adjuvant chemoagents,
including bevacizumab, temozolomide, and anti-epidermal factor (125)-mAB 425,
on the overall survival times was evaluated in four studies [34, 42, 44, 46]. In 2012,
Conti et al. compared the effect of a combination of temozolomide and Cyberknife
SRS with that of Cyberknife SRS alone on the overall survival times of patients with
recurrent GBMs [34]. The progression-free survival time and median survival time
in patients who received the adjuvant temozolomide and Cyberknife SRS were 7
and 12 months, respectively. The patients who received Cyberknife SRS alone had a
progression-free survival time and median survival time of only 4 and 7 months,
respectively. In the bevacizumab era, Yazici et al. revealed that the median survival
time in 37 patients with recurrent GBMs was 10.6 months, whereas the median
progression-free survival time was 7.9 months [44]. A tumor volume less than 24 cc
was the only significant prognostic factor associated with overall survival times.
4. Discussion
4.1 The role of SRS for recurrent GBMs
GBM is an incurable disease with local progression in the majority of patients.
The management of recurrent GBMs is a clinically challenging problem, and treat-
ment options are limited [7, 10]. Although reoperation with gross-total removal of
the tumor has been shown to improve the overall survival time in patients with
recurrent GBMs, surgery may not be preferred for patients with tumors in the
eloquent area, older age, or lower performance status [8]. Re-irradiation offers an
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alternative option for treating recurrent GBMs. In a systematic review and meta-
analysis of re-irradiation with external beam radiotherapy for recurrent GBMs,
Kazmi et al. showed that the 6- and 12-month overall survival times from the time
of re-irradiation were 70 and 34%, respectively, whereas the 6- and 12-month
progression-free survival times were 40 and 16%, respectively [11]. The overall
toxicity rate was low, ranging from 4 to 10%.
SRS has the ability to combine surgical and radio-oncological treatments to
deliver a high dose of focused radiation on the focal tumor lesion and spare the
adjacent normal anatomical structures. For recurrent GBMs, the majority of tumors
tend to grow within 2 cm of the contrast-enhancing lesion border, and SRS seems to
be a reasonable tool to add radiation boost for the focal lesion followed by the
standard treatment of initial radiation with 60 Gy in 30 fractions [4, 13]. In our
present review, despite the different SRS modalities with the median prescribed
dose ranging from 6 to 30 Gy, the overall survival time from the treatment of SRS
ranged from 3.9 to 17.9 months, where the progression-free survival time from the
treatment of SRS ranged from 2.1 to 14.9 months. Severe prognostic factors, such as
small tumor volume, younger age, higher KPS score, and lower RPA class, were
mostly suggested to be significantly associated with the overall survival time in
patients with recurrent GBMs treated with SRS. These results showed that re-
irradiation with the SRS modality are an alternative and feasible method to manage
patients with recurrent GBMs.
4.2 The impact of SRS and adjuvant temozolomide for recurrent GBMs
Since 2005, temozolomide, which is an alkylating agent, is the most important
FDA-approved chemoagent for the standard treatment of patients with newly diag-
nosed GBMs [1, 4]. The median overall survival time significantly improved from
12.1 to 14.6 months after the patients with newly diagnosed GBMs received combined
treatments with radiotherapy and adjuvant temozolomide. However, the disease
frequently progresses within 6–9 months, and the 2-year survival rate is less than 25%
[62]. The failure of temozolomide treatment has been found to be associated with the
expression of MGMT protein [63–65]. Among the GBM patients with a methylated
MGMT promoter, the median overall survival time was 21.7 months after treatment
with radiotherapy and temozolomide, whereas the median survival time was
15.3 months in the unmethylated group treated with radiotherapy alone [64].
Due to the blood-brain barrier, temozolomide rechallenge is considered to be a
reasonable option in patients with recurrent GBMs. In this review, the combination
of SRS and temozolomide was employed in three studies [34, 42, 47]. Cyberknife
SRS was performed in two studies, and the other study used the Gamma Knife SRS.
The median overall survival time ranged from 9 to 15.5 months, and the median
progression-free survival time was approximately 7 months after the time of SRS
treatment. In 2012, Conti et al. analyzed the effect of adjuvant temozolomide in
recurrent GBM patients treated with Cyberknife SRS [34]. The median overall
survival time significantly improved from 7 to 12 months, whereas the median
progression-free survival time improved from 4 to 7 months. Based on 57 recurrent
GBM patients, Kim et al. also showed that the improved median overall survival
time and progression-free survival time were 15.5 and 6 months, respectively [47].
Otherwise, in a retrospective review of 61 patients who received Gamma Knife SRS
as a salvage treatment at the time of the first progression, Kim et al. showed that the
median overall survival time was 14 months in the methylated MGMT promoter
group and 9 months in the unmethylated group [53]. Methylation of the MGMT
promoter was significantly corrected with better overall survival times and
progression-free survival times. The results mentioned above indicated that the
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combination of salvage SRS and adjuvant temozolomide may offer an important
treatment option to improve the overall survival times in patients with recurrent
GBMs.
4.3 The impact of SRS and adjuvant bevacizumab for recurrent GBMs
Bevacizumab is a recombinant human monoclonal antibody that acts against the
vascular endothelial growth factor to prevent the growth and maintenance of tumor
blood vessels. In 2009, bevacizumab was approved by the USFDA for the treatment
of patients with recurrent GBMs [66, 67]. The use of bevacizumab demonstrated a
radiological response of up to 40% [68]. However, in a large prospective phase III
trial, the use of adjuvant bevacizumab revealed only improvement in the
progression-free survival times from 1.5 to 4.2 months but not in the overall sur-
vival times [69]. In a systematic review and meta-analysis, Diaz et al. showed that
the survival advantage of bevacizumab at recurrence was limited to 4 months [70].
Although bevacizumab may reduce steroid requirements, there was no additional
benefit in the health-related quality of life. The role of bevacizumab in combination
with other cytotoxic chemoagents remains unclear.
The role of adjuvant bevacizumab in patients with recurrent GBMs treated with
SRS has been reported in nine studies, which were included in our review [35, 37,
39, 40, 44, 46, 49, 55, 59]. The median overall survival time ranged from 5.3 to
17.9 months, whereas the median progression-free survival time ranged from 3.9 to
14.9 months. The comparison of SRA with or without adjuvant bevacizumab was
investigated in two studies [35, 37]. Among 49 patients with recurrent GBMs,
Cuneo et al. showed that the median overall survival time was 11.2 months in
patients receiving SRS and adjuvant bevacizumab and 3.9 months in patients
receiving SRS therapy alone [35]. The progression-free survival time also improved
from 2.1 to 5.2 months. In a case-controlled study of patients with recurrent GBMs
treated with SRS and adjuvant bevacizumab plus temozolomide or irinotecan, Park
et al. also showed that the median overall survival time and progression-free sur-
vival time improved from 12.2 to 17.9 months and 6.7 to 14.9 months, respectively
[37]. In a retrospective study and review of the literature, Morris et al. reported that
the dual role of bevacizumab and radiosurgery had a benefit in the overall survival
times (11.2–17.9 months) and progression-free survival times (3.9–14.9 months).
These results showed the potential therapeutic effect of adjuvant bevacizumab in
combination with other treatment modalities, such as cytotoxic chemoagents or
salvage SRS, in patients with recurrent GBMs.
4.4 The future of SRS for recurrent GBMs
With the advance of molecular diagnostic techniques, newly diagnosed GBMs
should be classified based on the mutant status of isocitrate dehydrogenase 1
defined by the updated guidelines of the World Health Organization in 2016 [71].
These molecular profiles influence the overall survival time and the possible thera-
peutic effects of chemoagents. Similar to the recurrent GBMs, several main mole-
cules, such as MLH1 [72], CASP8 [73], MSH2 [74], and P53 [74], were found to be
different from primary GBMs [75]. The molecular features, intra-tumor heteroge-
neity, immunogenicity, and microenvironment around the tumor contribute to the
clinical prognostic outcomes in patients with recurrent GBMs [7, 10]. Reoperation,
re-chemotherapy, and re-irradiation currently remain as the standard treatments
for most patients with recurrent GBMs [2, 7, 10, 11]. A growing body of literature,
including our current review, demonstrates the tolerability and efficacy of salvage
SRS for recurrent GBMs, which did not inhibit re-irradiation, followed by a total of
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60 Gy typically applied in the first-line treatment [59]. Although younger age is
commonly considered as an important independent prognostic factor that is associ-
ated with survival, the selected criteria of salvage SRS for better outcomes need to
be investigated in further large prospective studies. In the future, individualized
precise multi-modality treatment will play an important role in patients with
recurrent GBMs, including the combination of cytotoxic chemotherapy, angiogen-
esis inhibitors, or immunotherapy [76]. Salvage SRS with a combination of other
treatment modalities may offer an alternative therapeutic method to manage
patients with recurrent GBMs.
5. Conclusion
Our review suggests that salvage SRS is an important treatment protocol for
managing patients with recurrent GBMs. The irradiation doses provided by SRS
may improve the clinical outcome of patients with recurrent GBMs, which is not
hampered by the standard case of 60 Gy prescribed for newly diagnosed GBMs. The
dual role of salvage SRS and other cytotoxic chemoagents, such as temozolomide
and bevacizumab, also seems to be effective in the management of recurrent GBMs.
Further application of salvage SRS combined with other chemoagents or a new
treatment modality needs to be investigated.
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